DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is a collection of 2,320 pre-approved bioactive compounds designed for high-throughput screening (HTS) and high-content screening (HCS) workflows (ApexBio). All compounds are approved by major regulatory agencies including the FDA, EMA, HMA, CFDA, and PMDA, or are listed in globally recognized pharmacopeias. The library covers diverse modes of action such as enzyme inhibition, receptor modulation, and signaling pathway regulation. Compounds are provided as 10 mM DMSO solutions, stable for up to 24 months at -80°C, and are available in multiple assay-ready formats. The resource enables rapid drug repositioning, target identification, and mechanistic studies in cancer, neurodegenerative, and rare disease models (Lim et al., 2022).

Biological Rationale

Drug discovery is challenged by high attrition rates and long development timelines. Screening libraries of clinically approved drugs can accelerate identification of new therapeutic indications by leveraging known safety and pharmacological profiles (Lim et al., 2022). The DiscoveryProbe™ FDA-approved Drug Library consolidates 2,320 compounds with established regulatory approval, reducing the risk of adverse events in downstream translational studies. Inclusion of molecules with diverse mechanisms—such as kinase inhibitors, ion channel modulators, and proteasome inhibitors—enables interrogation of multiple biological pathways, supporting applications ranging from cancer to metabolic and neurodegenerative diseases (internal source). This strategy aligns with evidence that repositioning existing drugs can rapidly yield new therapies, especially where de novo development is impractical.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library encompasses compounds acting as:

• Receptor agonists and antagonists: e.g., beta-blockers, opioid receptor antagonists.
• Enzyme inhibitors: e.g., kinase inhibitors (imatinib), proteasome inhibitors (bortezomib, ixazomib).
• Ion channel modulators: e.g., calcium and potassium channel blockers.
• Signal transduction regulators: e.g., mTOR inhibitors, JAK inhibitors.

Each compound is annotated with its primary target(s), regulatory status, and mechanism, supporting rational experimental design. For example, proteasome inhibitors disrupt protein degradation, leading to apoptosis in malignant cells (Lim et al., 2022). Kinase inhibitors modulate phosphorylation cascades critical in cell proliferation and survival. The standardized 10 mM DMSO format ensures compatibility with automated liquid handling systems and multi-well plate-based assays.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 unique, pre-approved bioactive compounds, each traceable to FDA, EMA, HMA, CFDA, or PMDA regulatory listings (product page).
• Second-generation proteasome inhibitors such as ixazomib, included in the library, have demonstrated synergistic anti-tumor activity in combination with CDK inhibitors in hepatocellular carcinoma (HCC) models (Lim et al., 2022, DOI).
• All compounds are provided as 10 mM solutions in DMSO, with stability confirmed for 12 months at -20°C and 24 months at -80°C, supporting long-term storage and reproducibility (ApexBio).
• The library enables high-throughput screening (HTS) and high-content screening (HCS) using formats such as 96-well microplates or deep-well plates, facilitating rapid assay integration (internal source).
• Drug repositioning screens using libraries of FDA-approved compounds have led to the identification of new treatment strategies for oncology and neurodegenerative diseases (Lim et al., 2022, DOI).

This article extends previous coverage by providing a detailed, mechanism-based mapping of library contents and their translational relevance, compared to the general overviews in this internal article and this resource.

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports a wide range of research and translational applications:

• Drug repositioning screening: Identify novel uses for existing drugs in new disease indications.
• Pharmacological target identification: Map phenotypic responses to specific molecular targets across disease models.
• Cancer research drug screening: Accelerate preclinical evaluation of compounds in solid and hematological malignancies (Lim et al., 2022).
• Neurodegenerative disease drug discovery: Screen for modulators of pathways implicated in Alzheimer’s, Parkinson’s, and ALS.
• Signal pathway regulation and enzyme inhibitor screening: Systematically interrogate kinase, proteasome, and epigenetic regulator pathways.

Limitations include the restriction to clinically approved or pharmacopeia-listed compounds, which may exclude novel chemical entities or investigational drugs. The library is not intended for direct therapeutic use in patients or for evaluating uncharacterized toxicity. It is best suited for in vitro and ex vivo screening, with subsequent validation required in preclinical models.

Common Pitfalls or Misconceptions

• Not all therapeutic classes (e.g., biologics, peptides >2 kDa) are represented; the library focuses on small molecules.
• Compounds are not intended for in vivo administration without further pharmacological and toxicological validation.
• Approved status does not guarantee efficacy in new indications; repositioning hits require rigorous preclinical and clinical follow-up.
• Enzyme inhibitors included may show off-target effects not previously observed in original indications.
• Stability claims (12–24 months) are valid only under specified storage conditions (e.g., -20°C, -80°C); deviations can compromise compound integrity.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is supplied as pre-dissolved 10 mM DMSO solutions in a variety of formats:

• 96-well microplates (standard for HTS)
• Deep well plates (for larger compound volumes)
• 2D barcoded screw-top tubes (for automated tracking and biobanking)

Compounds are shipped on blue ice for evaluation samples and at room temperature or on blue ice for other sizes upon request. Upon arrival, plates and tubes should be stored at -20°C (up to 12 months) or -80°C (up to 24 months) for optimal stability. Compounds are compatible with robotic liquid handling and automated assay platforms, supporting both phenotypic and target-based screening. The library's standardized format ensures reproducibility across multi-site studies and supports integration with cheminformatics and screening data pipelines. For an in-depth workflow guide and troubleshooting, see this internal article, which this analysis updates by detailing compound stability and assay compatibility parameters.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) offers a robust platform for high-throughput drug repositioning, pharmacological target identification, and mechanistic studies. By leveraging a curated compendium of regulatory-approved compounds, researchers can accelerate translational discovery and de-risk early-stage drug development. The library's compatibility with HTS and HCS workflows, flexible formats, and validated stability make it a cornerstone resource for academic and industrial research. Future directions include integrating additional annotation layers (e.g., omics profiles, resistance data) and expanding coverage to emerging drug classes. For detailed ordering and technical information, visit the DiscoveryProbe™ FDA-approved Drug Library product page.